Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01359566 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
A Phase 3 study of Multiple Sclerosis, sponsored by XenoPort.
- Completed
- Registry status
- Phase 3
- Development phase
- 228
- Enrollment target
- 20
- Study locations
NCT01359566: Completed Phase 3 study of Multiple Sclerosis, sponsored by XenoPort.
NCT01359566 is a Phase 3 study of Multiple Sclerosis that has completed, run by XenoPort. The registered enrollment target is 228 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01359566, a Phase 3 study of Multiple Sclerosis, has completed, sponsored by XenoPort.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 228 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).
Primary Outcome
numerical score
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Arbaclofen placarbil 15 mg BID
- DRUG Arbaclofen placarbil 30 mg BID
- DRUG Arbaclofen placarbil 45 mg BID
Study Locations (20)
Florida
- XenoPort Clinical Site - Port Charlotte
- XenoPort Clinical Site - Sarasota
- XenoPort Clinical Site - St. Petersburg
- XenoPort Clinical Site - Tampa
New York
- XenoPort Clinical Site - Albany
- XenoPort Clinical Site - Patchogue
- XenoPort Clinical Site - Plainview
Arizona
- XenoPort Clinical Site - Phoenix
- XenoPort Clinical Site - Tucson
California
- XenoPort Clinical Site - Berkeley
- XenoPort Clinical Site - San Diego
Michigan
- XenoPort Clinical Site - Bingham Farms
- XenoPort Clinical Site - Detroit
Colorado
- XenoPort Clinical Site - Denver
Illinois
- XenoPort Clinical Site - Lake Barrington
Indiana
- XenoPort Clinical Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-02 |
| Phase | Phase 3 |
What the finished NCT01359566 record still lists
NCT01359566 is an interventional study that assigns participants to a tested intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01359566 names 20 study sites across 12 states, led by Florida, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT01359566 about?
NCT01359566 is a clinical study titled "Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis". To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).
What is the current status of trial NCT01359566?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 228 participants. The study started on 2011-05. Estimated completion is 2013-02.
What conditions does trial NCT01359566 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT01359566?
The interventions under investigation include: Placebo (DRUG), Arbaclofen placarbil 15 mg BID (DRUG), Arbaclofen placarbil 30 mg BID (DRUG), Arbaclofen placarbil 45 mg BID (DRUG).
Who is sponsoring clinical trial NCT01359566?
This trial is sponsored by XenoPort, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01359566 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01359566's enrollment target sits among peer trials
228 73rd of 315 higher than 243 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 3
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia